about
Multicenter Quality Control for the Detection of Hepatitis C Virus RNA in Seminal Plasma SpecimensPegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial[Complementary treatments of chronic viral hepatitis C].Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon.Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.Multicenter quality control of hepatitis C virus protease inhibitor resistance genotypingSystemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.Herpes zoster: Risk and prevention during immunomodulating therapy.IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells.Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity.Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?Home-based urinary HPV DNA testing in women who do not attend cervical cancer screening clinics.IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells.Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study.Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania.Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
P50
Q27473329-9A34C954-B185-45D8-9140-DE867FEA5F9BQ28298301-837333E6-C2EC-4764-B12F-1D515ED2776CQ33370676-CE26ED89-2EEF-46F8-8E74-3A64E128E857Q34445911-E86394A3-C9A0-4D46-BEE3-2EC40992250FQ35050618-004327DE-0A7D-44FF-B38E-6D71E7F29FC1Q36342175-AC1567B7-3F33-4067-A17D-1F6D53C91BB0Q36826639-0CC46624-CBD7-4196-B221-3CDCC443AF56Q38190322-D6E67C39-3C78-442A-844A-4589AFE1D498Q38860232-E1A6A7DA-D7DB-41F6-8337-DFC6CB7F3444Q38971211-2C8135C9-66FA-41BB-AB3A-A756F52CCFEFQ40511273-035694BC-A2C8-4398-85BC-891FF93E9EB2Q40563453-529CC566-5829-4E17-89D2-008FC776AEADQ40858836-827100A1-A246-431B-A9F1-3AF58D161590Q41239808-BA6024D5-B67A-4E0A-994C-1378EFB0DD89Q41756934-0A7FB578-7FEE-4D58-836F-0D681BF8219EQ42288543-21AF2028-F98C-4D5D-AFCE-075CE5140379Q42981097-E0469DA9-F801-425A-91F4-BC4B4E75FF39Q42992084-D7EC5B73-6DDA-4C58-AE07-BF3CAA663A53Q43974843-4281345B-19AE-473B-8B68-6D2C1E5D29C5Q44304867-80DAD848-EB91-4354-9E19-EE706F711777Q45394175-585CE6FF-5486-4F6D-9E3A-9A6C808E6D8DQ45422517-3E03440E-C49F-4B7B-881D-29541AD5A26E
P50
name
Françoise Lunel-Fabiani
@ast
Françoise Lunel-Fabiani
@en
Françoise Lunel-Fabiani
@nl
type
label
Françoise Lunel-Fabiani
@ast
Françoise Lunel-Fabiani
@en
Françoise Lunel-Fabiani
@nl
prefLabel
Françoise Lunel-Fabiani
@ast
Françoise Lunel-Fabiani
@en
Françoise Lunel-Fabiani
@nl